Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. Offered by National Institutes of Health; applications due January 7, 2027.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- Not specified by funder
- Deadline
- January 7, 2027
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The...
Full requirements and application instructions: official listing.
Similar Open Grants
Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed)
National Institutes of Health
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Translational Neural Devices (R61/R33 - Clinical Trial Optional)
National Institutes of Health
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
National Institutes of Health
NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
National Institutes of Health
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)
National Institutes of Health
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
National Institutes of Health
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
National Institutes of Health
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health